PE20050335A1 - Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion - Google Patents
Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacionInfo
- Publication number
- PE20050335A1 PE20050335A1 PE2004000757A PE2004000757A PE20050335A1 PE 20050335 A1 PE20050335 A1 PE 20050335A1 PE 2004000757 A PE2004000757 A PE 2004000757A PE 2004000757 A PE2004000757 A PE 2004000757A PE 20050335 A1 PE20050335 A1 PE 20050335A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- diona
- thiazolidin
- pyridyl
- benzyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE: a) UNA PRIMERA COMPOSICION Y b) UNA SEGUNDA COMPOSICION. CADA COMPOSICION COMPRENDE UNA BASE DEBIL Y UN VEHICULO Y AMBAS ESTAN DISPUESTAS A LIBERAR EL FARMACO (ROSIGLITAZONA) A DIFERENTES VELOCIDADES DE LIBERACION INDEPENDIENTE DEL pH. LA VELOCIDAD DE LIBERACION DEL FARMACO DE LA PRIMERA COMPOSICION ES MAYOR QUE LA SEGUNDA. LA COMPOSICION (a) ES DE LIBERACION INMEDIATA Y LA COMPOSICION (b) ES DE LIBERACION MODIFICADA. SE REFIERE ADEMAS A UNA TERCERA COMPOSICION QUE NO COMPRENDE NINGUN FARMACO Y ES UNA COMPOSICION ENTERICA QUE COMPRENDE UNA O MAS ABERTURAS QUE SE EXTIENDE EN FORMA SUSTANCIAL EXPONIENDO AL MENOS UNA SUPERFICIE DE LA COMPOSICION (a) O (b). LA BASE DEBIL FARMACEUTICAMENTE ACEPTABLE ES 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA. SE REFIERE ADEMAS A UN PROCEDIMIENTO PARA LA PREPARACION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49338803P | 2003-08-07 | 2003-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050335A1 true PE20050335A1 (es) | 2005-06-01 |
Family
ID=34135242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000757A PE20050335A1 (es) | 2003-08-07 | 2004-08-05 | Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion |
Country Status (25)
Country | Link |
---|---|
US (1) | US20070134326A1 (es) |
EP (1) | EP1660049A2 (es) |
JP (1) | JP2007501773A (es) |
KR (1) | KR20060113650A (es) |
CN (2) | CN101239047A (es) |
AP (1) | AP2006003488A0 (es) |
AR (1) | AR045330A1 (es) |
AU (1) | AU2004262926B2 (es) |
BR (1) | BRPI0413374A (es) |
CA (1) | CA2534546A1 (es) |
EA (2) | EA200701409A1 (es) |
EC (1) | ECSP066318A (es) |
IL (1) | IL173176A0 (es) |
IS (1) | IS8336A (es) |
MA (1) | MA27980A1 (es) |
MX (1) | MXPA06001407A (es) |
NO (1) | NO20061018L (es) |
NZ (1) | NZ544696A (es) |
OA (1) | OA13230A (es) |
PE (1) | PE20050335A1 (es) |
SG (1) | SG145717A1 (es) |
TW (1) | TW200517127A (es) |
UY (1) | UY28457A1 (es) |
WO (1) | WO2005013935A2 (es) |
ZA (1) | ZA200600521B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
GB0502475D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
GB0502479D0 (en) * | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
BRPI1007945C8 (pt) | 2009-02-13 | 2021-05-25 | Romark Laboratories Lc | formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral |
AU2011208745B2 (en) | 2010-01-20 | 2013-11-14 | Glaxo Group Limited | Novel retigabine composition |
CN103948557A (zh) * | 2014-04-08 | 2014-07-30 | 闻晓光 | 一种新型控释片 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
FR2655266B1 (fr) * | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
IT1264517B1 (it) * | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US20020006939A1 (en) * | 1997-10-13 | 2002-01-17 | Smithkline Beecham P.L.C. | Use of thiazolidinediones for the treatment of hyperglycaemia |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
DE69939485D1 (de) * | 1998-11-12 | 2008-10-16 | Smithkline Beecham Plc | Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin |
EP1278513B1 (en) * | 2000-05-01 | 2007-07-18 | Aeropharm Technology, LLC | A core formulation |
GB0117618D0 (en) * | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
MY139719A (en) * | 2002-02-12 | 2009-10-30 | Glaxo Group Ltd | Oral dosage form for controlled drug release |
-
2004
- 2004-08-05 AR ARP040102794A patent/AR045330A1/es not_active Application Discontinuation
- 2004-08-05 UY UY28457A patent/UY28457A1/es not_active Application Discontinuation
- 2004-08-05 PE PE2004000757A patent/PE20050335A1/es not_active Application Discontinuation
- 2004-08-05 TW TW093123415A patent/TW200517127A/zh unknown
- 2004-08-06 KR KR1020067002663A patent/KR20060113650A/ko not_active Application Discontinuation
- 2004-08-06 CA CA002534546A patent/CA2534546A1/en not_active Abandoned
- 2004-08-06 BR BRPI0413374-9A patent/BRPI0413374A/pt not_active Application Discontinuation
- 2004-08-06 AP AP2006003488A patent/AP2006003488A0/xx unknown
- 2004-08-06 MX MXPA06001407A patent/MXPA06001407A/es unknown
- 2004-08-06 WO PCT/EP2004/008843 patent/WO2005013935A2/en active Application Filing
- 2004-08-06 AU AU2004262926A patent/AU2004262926B2/en not_active Ceased
- 2004-08-06 CN CNA2008100088784A patent/CN101239047A/zh active Pending
- 2004-08-06 CN CNA2004800226534A patent/CN1832729A/zh active Pending
- 2004-08-06 OA OA1200600040A patent/OA13230A/en unknown
- 2004-08-06 EA EA200701409A patent/EA200701409A1/ru unknown
- 2004-08-06 EA EA200600377A patent/EA011508B1/ru not_active IP Right Cessation
- 2004-08-06 NZ NZ544696A patent/NZ544696A/en unknown
- 2004-08-06 SG SG200805824-0A patent/SG145717A1/en unknown
- 2004-08-06 JP JP2006522328A patent/JP2007501773A/ja not_active Withdrawn
- 2004-08-06 EP EP04763874A patent/EP1660049A2/en not_active Withdrawn
- 2004-08-06 US US10/567,146 patent/US20070134326A1/en not_active Abandoned
-
2006
- 2006-01-16 IL IL173176A patent/IL173176A0/en unknown
- 2006-01-18 ZA ZA200600521A patent/ZA200600521B/en unknown
- 2006-01-25 EC EC2006006318A patent/ECSP066318A/es unknown
- 2006-02-07 MA MA28777A patent/MA27980A1/fr unknown
- 2006-03-01 NO NO20061018A patent/NO20061018L/no not_active Application Discontinuation
- 2006-03-02 IS IS8336A patent/IS8336A/is unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP066318A (es) | 2006-07-28 |
ZA200600521B (en) | 2007-01-31 |
TW200517127A (en) | 2005-06-01 |
US20070134326A1 (en) | 2007-06-14 |
BRPI0413374A (pt) | 2006-10-17 |
EA011508B1 (ru) | 2009-04-28 |
CA2534546A1 (en) | 2005-02-17 |
WO2005013935A3 (en) | 2005-07-14 |
AR045330A1 (es) | 2005-10-26 |
AU2004262926A1 (en) | 2005-02-17 |
MA27980A1 (fr) | 2006-07-03 |
EP1660049A2 (en) | 2006-05-31 |
EA200600377A1 (ru) | 2006-08-25 |
NZ544696A (en) | 2009-03-31 |
CN101239047A (zh) | 2008-08-13 |
SG145717A1 (en) | 2008-09-29 |
WO2005013935A2 (en) | 2005-02-17 |
KR20060113650A (ko) | 2006-11-02 |
OA13230A (en) | 2006-12-13 |
MXPA06001407A (es) | 2006-05-15 |
JP2007501773A (ja) | 2007-02-01 |
IS8336A (is) | 2006-03-02 |
EA200701409A1 (ru) | 2007-10-26 |
AU2004262926B2 (en) | 2009-11-19 |
NO20061018L (no) | 2006-03-01 |
AP2006003488A0 (en) | 2006-02-28 |
UY28457A1 (es) | 2005-03-31 |
IL173176A0 (en) | 2006-06-11 |
CN1832729A (zh) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606768A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
DK1414451T3 (da) | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist | |
AR046811A1 (es) | Formas de dosificacion oral de ziprasidona de liberacion sostenida | |
HRP20020416B1 (en) | Novel composition and use | |
ECSP055569A (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
HRP20010343B1 (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent | |
DE60319252D1 (de) | Formulierung von acetaminophen und tramadol mit verzögerter freisetzung | |
IL173078A0 (en) | Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form | |
BRPI0607803A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
AP1545A (en) | Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione. | |
AR053731A1 (es) | Aromatizacion de gomas de mascar que contienen farmacos | |
PE20050335A1 (es) | Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion | |
BR0114196A (pt) | Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas. | |
CO2022019160A2 (es) | Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina | |
MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
CR8748A (es) | Una composicion farmaceutica antimicobacteriana | |
CY1105252T1 (el) | Το υδροχλωρικο αλας της 5-[4-[2-(ν-μεθυλο-ν-(2-πυριδυλο)αμινο)-αιθοξυ]βενζυλο]θειαζολιδινο-2,4-διονης | |
SE9902935D0 (sv) | Pharmaceutical compositions | |
AR038417A1 (es) | Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral | |
AR015120A1 (es) | Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica | |
CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
ATE337313T1 (de) | 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz | |
ECSP034469A (es) | Compuesto farmaceutico novedoso | |
PT1446404E (pt) | Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos | |
CY1107421T1 (el) | Τρυγικα αλατα παραγωγου θειαζολιδινοδιονης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |